专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050054654A1 VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines 失效
标题翻译： VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶
公开(公告)号：US20050054654A1
公开(公告)日：2005-03-10
申请号：US10870491
申请日：2004-06-18
申请人： Andreas Huth , Ludwig Zorn , Martin Krueger , Stuart Ince , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Ludwig Zorn , Martin Krueger , Stuart Ince , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： C07D213/61 , C07D213/73 , C07D213/74 , C07D213/75 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/12 , C07D413/04 , C07D413/14 , C07D417/04 , C07D43/02 , A61K31/497 , A61K31/501 , A61K31/506 , C07D41/02
CPC分类号： C07D213/61 , C07D213/73 , C07D213/74 , C07D213/75 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/12 , C07D413/04 , C07D413/14 , C07D417/04
摘要： VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver; mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.
摘要翻译：描述了VEGFR-2和VEGFR-3抑制性邻氨基苯酰胺吡啶酰胺，其作为用于治疗由持续血管发生引起的疾病的药物的制备和用途，以及用于制备化合物的中间产物。根据本发明的化合物可用于或在肿瘤或转移生长的情况下，牛皮癣，卡波西肉瘤，再狭窄，例如支架诱导的再狭窄，子宫内膜异位，克罗恩病，霍奇金病，白血病; 关节炎，如类风湿关节炎，血管瘤，血管纤维瘤; 眼睛疾病如糖尿病性视网膜病变，新生血管性青光眼; 肾脏疾病如肾小球性肾炎，糖尿病肾病，恶性肾硬化，血栓性微血管病综合征，移植排斥反应和肾小球病; 纤维化疾病，如肝硬化; 肾小球膜细胞增生性疾病，动脉硬化，神经组织损伤，以及球囊导管治疗后血管假体中或使用机械装置用于保持血管开放（例如，支架）作为免疫抑制剂的抑制，作为免疫抑制剂无疤痕愈合，老年角化病和接触性皮炎的支持。在淋巴管生成的情况下，根据本发明的化合物也可以用作VEGFR-3抑制剂。

2. 发明申请

US20070135489A1 Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridones 审中-公开
标题翻译： Vegfr-2和vegfr-3抑制性邻氨基苯甲酰胺吡啶酮
公开(公告)号：US20070135489A1
公开(公告)日：2007-06-14
申请号：US11654643
申请日：2007-01-18
申请人： Andreas Huth , Martin Krueger , Ludwig Zorn , Stuart Ince , Rolf Bohlmann , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Martin Krueger , Ludwig Zorn , Stuart Ince , Rolf Bohlmann , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： A61K31/444 , A61K31/4412 , C07D213/62
CPC分类号： C07D213/64
摘要： Novel VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are selected.
摘要翻译：选择新型VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶酮及其作为用于治疗由持续性血管生成触发的疾病的药物的用途。

3. 发明申请

US20050049281A1 VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones 失效
标题翻译： VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶酮
公开(公告)号：US20050049281A1
公开(公告)日：2005-03-03
申请号：US10866078
申请日：2004-06-14
申请人： Andreas Huth , Martin Krueger , Ludwig Zorn , Stuart Ince , Rolf Bohlmann , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Martin Krueger , Ludwig Zorn , Stuart Ince , Rolf Bohlmann , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： A61K31/444 , C07D211/84 , C07D213/62
CPC分类号： C07D213/64
摘要： Novel VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are selected.
摘要翻译：选择新型VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶酮及其作为用于治疗由持续性血管生成引发的疾病的药物的用途。

4. 发明授权

US07202260B2 VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones 失效
标题翻译： VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶酮
公开(公告)号：US07202260B2
公开(公告)日：2007-04-10
申请号：US10866078
申请日：2004-06-14
申请人： Andreas Huth , Martin Krueger , Ludwig Zorn , Stuart Ince , Rolf Bohlmann , Karl Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Martin Krueger , Ludwig Zorn , Stuart Ince , Rolf Bohlmann , Karl Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： C07D401/01 , C07D213/02 , A61K31/44
CPC分类号： C07D213/64
摘要： Novel VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are selected.
摘要翻译：选择新型VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶酮及其作为用于治疗由持续性血管生成引发的疾病的药物的用途。

5. 发明授权

US07517894B2 VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines 失效
标题翻译： VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶
公开(公告)号：US07517894B2
公开(公告)日：2009-04-14
申请号：US10870491
申请日：2004-06-18
申请人： Andreas Huth , Ludwig Zorn , Martin Krueger , Stuart Ince , Karl Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Ludwig Zorn , Martin Krueger , Stuart Ince , Karl Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： A61K31/4439 , C07D401/04
CPC分类号： C07D213/61 , C07D213/73 , C07D213/74 , C07D213/75 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/12 , C07D413/04 , C07D413/14 , C07D417/04
摘要： VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver; mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.
摘要翻译：描述了VEGFR-2和VEGFR-3抑制性邻氨基苯酰胺吡啶酰胺，其作为用于治疗由持续血管发生引起的疾病的药物的制备和用途，以及用于制备化合物的中间产物。根据本发明的化合物可用于或在肿瘤或转移生长的情况下，牛皮癣，卡波西肉瘤，再狭窄，例如支架诱导的再狭窄，子宫内膜异位，克罗恩病，霍奇金病，白血病; 关节炎，如类风湿关节炎，血管瘤，血管纤维瘤; 眼睛疾病如糖尿病性视网膜病变，新生血管性青光眼; 肾脏疾病如肾小球性肾炎，糖尿病肾病，恶性肾硬化，血栓性微血管病综合征，移植排斥反应和肾小球病; 纤维化疾病，如肝硬化; 肾小球膜细胞增生性疾病，动脉硬化，神经组织损伤，以及球囊导管治疗后血管假体中或使用机械装置用于保持血管开放（例如，支架）作为免疫抑制剂的抑制，作为免疫抑制剂无疤痕愈合，老年角化病和接触性皮炎的支持。在淋巴管生成的情况下，根据本发明的化合物也可以用作VEGFR-3抑制剂。

6. 发明申请

US20070015794A1 VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines 失效
标题翻译： VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶
公开(公告)号：US20070015794A1
公开(公告)日：2007-01-18
申请号：US11525091
申请日：2006-09-22
申请人： Andreas Huth , Ludwig Zorn , Martin Kruger , Stuart Ince , Karl-Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Ludwig Zorn , Martin Kruger , Stuart Ince , Karl-Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： A61K31/444 , A61K31/44 , C07D401/02 , C07D213/72
CPC分类号： C07D213/72 , C07D401/02
摘要： VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.
摘要翻译：描述了VEGFR-2和VEGFR-3抑制性邻氨基苯酰胺吡啶酰胺，其作为用于治疗由持续血管发生引起的疾病的药物的制备和用途，以及用于制备化合物的中间产物。根据本发明的化合物可用于或在肿瘤或转移生长的情况下，牛皮癣，卡波西肉瘤，再狭窄，例如支架诱导的再狭窄，子宫内膜异位，克罗恩病，霍奇金病，白血病; 关节炎，如类风湿关节炎，血管瘤，血管纤维瘤; 眼睛疾病如糖尿病性视网膜病变，新生血管性青光眼; 肾脏疾病如肾小球性肾炎，糖尿病肾病，恶性肾硬化，血栓性微血管病综合征，移植排斥反应和肾小球病; 纤维化疾病，如肝硬化，肾小球膜细胞增生性疾病，动脉硬化，神经组织损伤，以及球囊导管治疗后血管再狭窄的抑制，血管修复术或机械装置用于保持血管开放的诸如例如作为免疫抑制剂的支架，作为无疤痕愈合的支持，老年角化病和接触性皮炎。在淋巴管生成的情况下，根据本发明的化合物也可以用作VEGFR-3抑制剂。

7. 发明授权

US07148357B2 VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines 失效
公开(公告)号：US07148357B2
公开(公告)日：2006-12-12
申请号：US10631018
申请日：2003-07-31
申请人： Andreas Huth , Ludwig Zorn , Martin Kruger , Stuat Ince , Karl-Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Ludwig Zorn , Martin Kruger , Stuat Ince , Karl-Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： C07D401/10
CPC分类号： C07D413/14 , C07D213/61 , C07D213/73 , C07D213/74 , C07D213/75 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/12 , C07D413/04 , C07D417/04
摘要： VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.

8. 发明授权

US07615565B2 VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines 失效
标题翻译： VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶
公开(公告)号：US07615565B2
公开(公告)日：2009-11-10
申请号：US11525091
申请日：2006-09-22
申请人： Andreas Huth , Ludwig Zorn , Martin Kruger , Stuat Ince , Karl-Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Ludwig Zorn , Martin Kruger , Stuat Ince , Karl-Heinz Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： A61K31/47 , C07D217/22
CPC分类号： C07D213/72 , C07D401/02
摘要： VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.
摘要翻译：描述了VEGFR-2和VEGFR-3抑制性邻氨基苯酰胺吡啶酰胺，其作为用于治疗由持续血管发生引起的疾病的药物的制备和用途，以及用于制备化合物的中间产物。根据本发明的化合物可用于或在肿瘤或转移生长的情况下，牛皮癣，卡波西肉瘤，再狭窄，例如支架诱导的再狭窄，子宫内膜异位，克罗恩病，霍奇金病，白血病; 关节炎，如类风湿关节炎，血管瘤，血管纤维瘤; 眼睛疾病如糖尿病性视网膜病变，新生血管性青光眼; 肾脏疾病如肾小球性肾炎，糖尿病肾病，恶性肾硬化，血栓性微血管病综合征，移植排斥反应和肾小球病; 纤维化疾病，如肝硬化，肾小球膜细胞增生性疾病，动脉硬化，神经组织损伤，以及球囊导管治疗后血管再狭窄的抑制，血管修复术或机械装置用于保持血管开放的诸如例如作为免疫抑制剂的支架，作为无疤痕愈合的支持，老年角化病和接触性皮炎。在淋巴管生成的情况下，根据本发明的化合物也可以用作VEGFR-3抑制剂。

9. 发明申请

US20060116380A1 Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors 失效
公开(公告)号：US20060116380A1
公开(公告)日：2006-06-01
申请号：US11265517
申请日：2005-11-03
申请人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp , Andreas Reichel
发明人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp , Andreas Reichel
IPC分类号： A61K31/506 , A61K31/501 , A61K31/4709 , A61K31/497 , A61K31/444 , C07D403/14 , C07D401/14
CPC分类号： C07D401/12
摘要： The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.

10. 发明申请

US20060264425A1 Novel anthranilamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors 失效
标题翻译：新型邻氨基苯甲酰胺吡啶脲作为血管内皮生长因子（VEGF）受体激酶抑制剂
公开(公告)号：US20060264425A1
公开(公告)日：2006-11-23
申请号：US11265516
申请日：2005-11-03
申请人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp
发明人： Rolf Bohlmann , Martin Haberey , Andreas Huth , Stuart Ince , Martin Krueger , Karl-Heinz Thierauch , Holger Hess-Stumpp
IPC分类号： A61K31/541 , A61K31/5377 , A61K31/496 , C07D417/14 , C07D413/14 , C07D403/14
CPC分类号： C07D213/75 , C07D401/12 , C07D401/14 , C07D491/10
摘要： The invention relates to novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis.
摘要翻译：本发明涉及作为VEGF受体激酶抑制剂的新型邻氨基苯甲酰胺吡啶脲，其作为用于预防或治疗由持续血管生成引发的疾病的药剂的生产和用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式